Germany's coalition government is backing away from the most contested parts of its medical cannabis reimbursement reform. Clarification amendments go before the Bundestag Health Committee on Wednesday, October 7. They would limit the mandatory six-month finished-medicine trial to patients whose condition is covered by a licensed product. That rule has effectively channelled new pain patients towards one drug: Vertanical's Exilby. The retreat comes as a Der Spiegel investigation asks how that Munich-made medicine won such a privileged market position.
The stakes are high. About 65,000 patients have already lost insurance cover for cannabis flower. The questions also reach beyond cannabis to how German health policy gets written. We've followed this story since the summer, and every new revelation makes it harder to dismiss as coincidence.
A Medical Cannabis Market Rewritten in Twelve Months
Germany's medical cannabis market changed more in one year than in the previous several combined. The first step came on May 30, 2026. That day the BfArM, the Federal Institute for Drugs and Medical Devices and Germany's federal drugs regulator, approved Vertanical's Exilby. Exilby is a plant-derived cannabis extract licensed for chronic lower back pain with a neuropathic component. Neuropathic pain is pain caused by damage to, or malfunction of, the nervous system itself.
Less than two months later, new cannabis provisions appeared in the BStabG (GKV-Beitragssatzstabilisierungsgesetz). The BStabG is a broad savings package designed to stabilise contribution rates in statutory health insurance. The Bundestag passed it on July 10, 2026, and it took effect on July 29, 2026.
The cannabis amendment was added late in the parliamentary process. It removed dried cannabis flower from GKV reimbursement entirely. GKV is Germany's statutory health insurance system, the public scheme that covers most of the population. Around 65,000 patients who already used flower lost cover overnight.
A new approval, a late amendment and a full-category ban, all inside twelve months, makes for an unusually fast shift. That speed is what investigators, opposition politicians and patient groups are now trying to explain.
How the Six-Month Trial Steered Pain Patients to Exilby
The flower ban was only half of the reform. The BStabG also requires doctors to put patients on a licensed cannabis-containing finished medicine for six months before they can prescribe a reimbursable extract. A finished medicine (Fertigarzneimittel) is an industrially manufactured, standardised product with its own marketing authorisation for specific conditions. A reimbursable extract is a cannabis extract dispensed by pharmacies on prescription. It has no such product-specific licence, but statutory insurers pay for it.
The numbers explain why this rule matters so much. According to BfArM's national survey of GKV cannabis prescriptions, 76.4% of patients cite chronic pain as their primary condition. Only four cannabis products hold a licence in Germany, and Exilby is the only one licensed for pain.
Exilby launched commercially in September 2026. By then it was already established as the first-line reimbursable option for pain treatment. For any new pain patient in the statutory system, Exilby was effectively compulsory for six months before any other cannabis treatment could be prescribed.
So the rule was written in general terms, but its practical effect was specific. The largest patient group in German medical cannabis was routed to a single manufacturer's product, approved just weeks before the law passed.
Key Dates Behind Germany's Cannabis Reimbursement Reform
The controversy over Germany's medical cannabis reform depends heavily on timing. Meetings, visits, approvals and legislative steps line up closely around Vertanical's Exilby, a cannabis extract licensed for neuropathic lower back pain. The table below sets out the documented sequence.
| Date | Event |
|---|---|
| June 21, 2024 | Federal Ministry of Health (BMG) meets Vertanical representatives, organised by a lobbying firm |
| July 15, 2024 | Exilby approval application submitted |
| Before the last federal election | Vertanical founder Clemens Fischer donates €560,000 to four centre parties |
| December 2025 | Bavarian Minister-President Markus Söder visits Vertanical's facility |
| March 2026 | Then-federal health minister Nina Warken visits Fischer in Gräfelfing |
| May 30, 2026 | BfArM approves Exilby |
| June 22, 2026 | G-BA chair Josef Hecken recommends the six-month trial, naming Exilby |
| June 30 / July 1, 2026 | Hecken resigns; Sonja Optendrenk takes over |
| July 10, 2026 | Bundestag passes the BStabG |
| July 29, 2026 | Flower ban and six-month trial take effect |
| September 2026 | Exilby launches commercially |
| October 7, 2026 | Health Committee hearing on clarification amendments |
No single entry proves wrongdoing. Taken together, though, they show how closely Exilby's regulatory path tracked the political calendar.
Lobby Contacts and Political Donations
Der Spiegel's August investigation and its follow-up last week focus on how Vertanical, a Munich-based manufacturer, built links with decision-makers before its product was approved. The most recent report says the Federal Ministry of Health (BMG) met Vertanical representatives on June 21, 2024. A lobbying firm organised the meeting.
According to an email seen by the publication, the meeting explicitly concerned Exilby's approval application. That application was submitted on July 15, 2024, less than a month after the meeting.
Earlier reporting covered the financial side. Vertanical founder Clemens Fischer donated €560,000 to the four main centre parties ahead of the last federal election:
- CSU: €200,000
- FDP: €200,000
- SPD: €100,000
- CDU: €60,000
The donations were legal and publicly disclosed. Fischer said he wanted to "strengthen the political centre." Nobody has alleged that the payments broke party-finance rules.
Still, the combination draws scrutiny. There were large donations across the parties that would later shape health policy, plus a lobbyist-arranged meeting about a pending approval. Critics are asking whether a first-time applicant received access that other companies did not.
Ministerial Visits and Requests for Status Updates
Two high-profile visits to Vertanical have become central to the row over Germany's cannabis reimbursement reform. In both cases, officials asked the drugs regulator for updates on Exilby's approval before the visit took place.
Markus Söder, December 2025
Bavarian Minister-President Markus Söder visited Vertanical's facility in December 2025. According to Der Spiegel, BfArM president Karl Broich told colleagues beforehand that he would need to answer questions on the state of the approval process. Broich also said the health ministry would want to be kept informed.
Nina Warken, March 2026
Three months later, in March 2026, then-federal health minister Nina Warken (CDU) visited Fischer at Vertanical's facility in Gräfelfing, just outside Munich. Vertanical documented the visit itself and posted a photo of the two online. Der Spiegel reports that ministry officials again asked BfArM for a status update on Exilby's approval beforehand.
A senior politician visiting a regional manufacturer is routine. Asking the regulator, ahead of time, where an approval stands is less routine. The visits fell between the July 2024 application and the May 2026 approval. That has led critics to ask whether political attention, intended or not, put pressure on the regulator's timetable.
Doubts Inside the Regulator
Exilby's approval is not a clean bill of health. The Federal Ministry of Health answered a parliamentary question from the Greens in writing, published as a Bundestag paper on September 23. In it, the ministry confirmed that Exilby received conditional approval. This is a marketing authorisation granted before the full evidence is in, on the understanding that the manufacturer will supply more data later. Exilby must now undergo a further efficacy study because of "remaining uncertainties regarding efficacy."
Der Spiegel's reporting goes further. It cites internal memos from BfArM staff. One notes that the Exilby decision rested on "the (oral) directive of management." Another records "considerable doubts about the benefit" of the medicine during the approval process.
Those memos give the story its sharpest edge. A product approved despite internal doubts about its benefit was, within weeks, written into law as the mandatory first step for most new pain patients.
Vertanical has defended the product. Asked about the doubts in August, the company pointed to two studies showing "significant pain reduction." A follow-up request about the lobby contacts went unanswered.
The G-BA Recommendation and the Missing Author
The six-month trial rule had a prominent supporter before it became law. The G-BA (Gemeinsamer Bundesausschuss, or Federal Joint Committee) is the body that sets reimbursement rules for Germany's statutory health insurance. On June 22, 2026, its then impartial chair, Professor Josef Hecken, told a Bundestag Health Committee hearing that he recommended a six-month finished-medicine trial. He specifically named Exilby as a possible alternative.
Eight days later, Hecken resigned from the G-BA. Sonja Optendrenk succeeded him on July 1. No public link has been established between the recommendation and the departure. Even so, the timing has drawn attention, given how closely the enacted law matched his proposal.
A more basic question remains open: who actually wrote the amendment? It was inserted into the BStabG only days before the bill passed on July 10, 2026. Government sources have given conflicting accounts of its authorship, and those accounts are now on the public record.
Legislative authorship matters. If a provision that creates a de facto monopoly for one product cannot be traced to a clear author, accountability breaks down.
A Ministry Denial With Narrow Edges
The Federal Ministry of Health has formally denied any contact with Vertanical or its parent group, Futrue, during Exilby's approval. The denial is worded carefully.
Greens health spokesperson Dr Paula Piechotta asked whether government officials had held "conversations or other contacts with representatives of Vertanical GmbH and/or FUTRUE GmbH" during the approval process. The ministry answered with one word: "No."
That answer covers neither the documented June 21, 2024 meeting nor Nina Warken's March 2026 visit to Vertanical's facility. The ministry told Der Spiegel that such exchanges are "not unusual, especially for companies without approval experience." It also argued that the June 2024 meeting fell outside the "approval process" the Greens asked about, because the formal application had not yet been filed. That filing came on July 15, 2024.
Technically, the defence rests on a narrow definition of when an approval process begins. Politically, it invites a follow-up question. Email evidence says the meeting explicitly concerned the Exilby application, so does it matter that the paperwork arrived three weeks later? Critics say a denial that relies on procedural timing rather than substance does little to settle the questions about access and influence.
What the Clarification Amendments Would Change
The coalition's clarification amendments go before the Bundestag Health Committee on Wednesday, October 7. They target the six-month finished-medicine trial, the rule requiring patients to use a licensed cannabis medicine for six months before receiving a reimbursable extract.
If the amendments pass, the trial would apply only where the patient's condition is actually covered by one of Germany's four licensed cannabis finished medicines. Here is how that compares with the current law:
| Patient group | Current rule (since July 29, 2026) | Proposed rule |
|---|---|---|
| Condition covered by a licensed finished medicine (e.g. neuropathic back pain) | Six-month finished-medicine trial required | Six-month trial still required |
| Condition outside licensed indications | Six-month trial required before extracts | Reimbursable extracts available immediately |
| Patients already stable on extracts | Continuity uncertain | May continue current treatment |
| Patients using dried flower | No GKV reimbursement | No change: still excluded |
Most German medical cannabis patients have conditions outside the four licensed indications, so they would benefit most. For them, the forced detour through a finished medicine would end.
The core of the Exilby question stays in place, however. Exilby is the only licensed product for pain, and pain accounts for 76.4% of GKV cannabis prescriptions. Patients whose pain falls within its licensed indication would still face the six-month trial.
Why Flower Patients Are Still Left Out
For the roughly 65,000 patients cut off from statutory cannabis flower reimbursement on July 29, 2026, the coalition's climbdown changes little. The clarification amendments address the six-month finished-medicine trial. They do not reverse the exclusion of dried flower from GKV coverage.
On paper, there is still a fallback. Patients with a life-threatening illness can apply to their insurer for flower to be covered as an emergency measure. That route was always narrow, and it now appears blocked in practice as well.
Apotheke Adhoc, a German pharmacy trade publication, reported on October 1 that the emergency door has effectively closed. The pricing agreement between pharmacies and insurers that made the route workable has lapsed. Without it, there is no agreed price for flower prescribed under the emergency provision. With no agreed price, there is in practice no reimbursement.
This is a common pattern in health policy: a legal entitlement that exists only on paper. A seriously ill patient may meet every criterion and still find that no pharmacy can bill the insurer. For flower patients, the realistic options are paying privately, switching to an extract or finished medicine, or waiting for further reform. Patient groups have pledged to keep pushing for that reform.
What Comes Next for German Medical Cannabis
The October 7 Health Committee hearing will show whether the coalition's softening goes through. The bigger questions are unlikely to go away with one vote. Several remain unresolved:
- Authorship: who drafted the late amendment that excluded flower and created the six-month trial?
- Regulatory independence: why did BfArM approve Exilby on "the (oral) directive of management" despite internal "considerable doubts about the benefit"?
- Ministerial contact: how does the health ministry's "No" fit with a documented meeting and a ministerial visit?
- Evidence: what will Exilby's required follow-up efficacy study show?
We're growers, not lobbyists, and our view is simple. Patients deserve decisions based on evidence, made transparently, with a clear author behind every line of law. Average is our enemy, and so is opacity. A medicine with unresolved efficacy questions should not become the compulsory gateway for most pain patients.
It's worth remembering that Germany's 2024 Cannabis Act lets adults grow up to three plants at home for personal use. Home cultivation does not replace medical supervision for anyone managing a serious condition. It does mean the plant itself remains accessible even while the insurance system fights over who pays for it.
We'll keep tracking every amendment and every revelation. Stay tuned to our blog for the next chapter.
Frequently asked questions
What is Exilby?
Exilby is a plant-derived cannabis extract made by Munich-based Vertanical. Germany's drugs regulator, BfArM, approved it on May 30, 2026, for chronic lower back pain with a neuropathic component. It received only conditional approval and must undergo a further efficacy study. It is currently the only licensed cannabis finished medicine for pain in Germany.
Why was cannabis flower removed from German statutory health insurance?
A late amendment to the BStabG, a health insurance savings law passed on July 10, 2026, removed dried flower from statutory reimbursement from July 29. Around 65,000 patients lost cover. Who drafted the amendment remains disputed, and government sources have given conflicting accounts of how it came to be added.
What would the proposed clarification amendments change?
The amendments would apply the mandatory six-month finished-medicine trial only to patients whose condition falls under one of Germany's four licensed cannabis medicines. Patients outside those indications could receive reimbursable extracts immediately, and patients already stable on extracts could continue. The exclusion of dried flower would stay in place.
Can seriously ill patients still get cannabis flower reimbursed?
In theory, yes. Patients with a life-threatening illness can apply for emergency coverage. In practice, the pricing agreement between pharmacies and insurers that supported this route has lapsed, according to an October 1 report by Apotheke Adhoc. With no agreed price, pharmacies cannot bill insurers, so reimbursement is effectively unavailable.
Did Germany's health ministry meet with Vertanical?
Der Spiegel reports a meeting on June 21, 2024, arranged by a lobbying firm and concerning Exilby's approval application. The ministry has denied any contacts during the approval process. It argues that this meeting came before the formal application was filed on July 15, 2024, and that such exchanges are not unusual.
Were Clemens Fischer's political donations legal?
Yes. The Vertanical founder gave €560,000 to the CSU, FDP, SPD and CDU ahead of the last federal election. The donations were legal and publicly disclosed. Fischer said he wanted to strengthen the political centre. The controversy concerns access and influence rather than any breach of party-finance law.
Europe